LSP’s portfolio company Orphazyme raises approximately €80 million in oversubscribed IPO
Summary
The shares are trading under the (permanent) ticker symbol ORPHA DC Equity.LSP, together with the ALS Investment Fund, financed Orphazyme in March 2017 and joined the companys Series B extension round. For more information, please visit www.orphazyme.comLSP is an independent European investment firm, providing financing for private and public life sciences companies. Since the late 1980s, LSPs management has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europes leading life sciences investors. The Fund was initiated by 3 Dutch ALS patients and is supported by a top-tier European VC firm, Life Sciences Partners.